The global market for Flow Cytometry in Oncology and Immunology was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Flow cytometry is a powerful technology that is widely used in both oncology and immunology research. It is a technique used to analyze the physical and chemical properties of cells in a heterogeneous population, by labeling and detecting specific molecules on the surface of cells. The resulting data can provide information about the number, size, and complexity of cells in a sample, as well as their phenotype and function.
In oncology, flow cytometry is often used to analyze cancer cells and to monitor the progression of the disease. For example, flow cytometry can be used to identify and quantify cancer stem cells, which are thought to be responsible for tumor initiation and recurrence. It can also be used to measure the expression of tumor-associated antigens, which are molecules expressed by cancer cells that can be targeted by immunotherapy.
Overall, flow cytometry is a versatile tool that has many applications in oncology and immunology research. It can provide valuable information about the biology of cells and their interactions with other cells and molecules, and can help researchers to develop new diagnostic and therapeutic approaches for cancer and other diseases
The global increase in HIV diagnoses is a significant market factor for flow cytometry, and this is because the flow cytometry technique is specifically used for HIV diagnosis. In flow cytometry, light scattering is utilized to identify cells. These cells receive particular markers known as CDs depending on the type of scattering (clusters of differentiation). The main market players are concentrating on creating new products, which is anticipated to propel market growth over the forecast year.
This report aims to provide a comprehensive presentation of the global market for Flow Cytometry in Oncology and Immunology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Flow Cytometry in Oncology and Immunology.
The Flow Cytometry in Oncology and Immunology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Flow Cytometry in Oncology and Immunology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Flow Cytometry in Oncology and Immunology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Agilent
ABYNTEK BIOPHARMA
Bio-Rad Laboratories
Cell Signaling Technology
Cytek Biosciences
Danaher Corporation,
DiaSorin S.p.A (Luminex Corporation),
Enzi Biochem Inc
Laboratory Corporation of America Holdings,
Merck KGaA
Miltenyi Biotec
NeoGenomics Laboratories
OPKO Health
Sony Group Corporation
Thermo Fisher Scientific Inc.
Segment by Type
Products
Services
Segment by Application
Immunology
Oncology
Solid Tumor
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Flow Cytometry in Oncology and Immunology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Flow Cytometry in Oncology and Immunology 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Products
1.2.3 Services
1.3 麻豆原创 by Application
1.3.1 Global Flow Cytometry in Oncology and Immunology 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Immunology
1.3.3 Oncology
1.3.4 Solid Tumor
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Flow Cytometry in Oncology and Immunology 麻豆原创 Perspective (2020-2031)
2.2 Global Flow Cytometry in Oncology and Immunology Growth Trends by Region
2.2.1 Global Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Flow Cytometry in Oncology and Immunology Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Flow Cytometry in Oncology and Immunology Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Flow Cytometry in Oncology and Immunology 麻豆原创 Dynamics
2.3.1 Flow Cytometry in Oncology and Immunology Industry Trends
2.3.2 Flow Cytometry in Oncology and Immunology 麻豆原创 Drivers
2.3.3 Flow Cytometry in Oncology and Immunology 麻豆原创 Challenges
2.3.4 Flow Cytometry in Oncology and Immunology 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Flow Cytometry in Oncology and Immunology Players by Revenue
3.1.1 Global Top Flow Cytometry in Oncology and Immunology Players by Revenue (2020-2025)
3.1.2 Global Flow Cytometry in Oncology and Immunology Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Flow Cytometry in Oncology and Immunology 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Flow Cytometry in Oncology and Immunology Revenue
3.4 Global Flow Cytometry in Oncology and Immunology 麻豆原创 Concentration Ratio
3.4.1 Global Flow Cytometry in Oncology and Immunology 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Flow Cytometry in Oncology and Immunology Revenue in 2024
3.5 Global Key Players of Flow Cytometry in Oncology and Immunology Head office and Area Served
3.6 Global Key Players of Flow Cytometry in Oncology and Immunology, Product and Application
3.7 Global Key Players of Flow Cytometry in Oncology and Immunology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Flow Cytometry in Oncology and Immunology Breakdown Data by Type
4.1 Global Flow Cytometry in Oncology and Immunology Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Flow Cytometry in Oncology and Immunology Forecasted 麻豆原创 Size by Type (2026-2031)
5 Flow Cytometry in Oncology and Immunology Breakdown Data by Application
5.1 Global Flow Cytometry in Oncology and Immunology Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Flow Cytometry in Oncology and Immunology Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Flow Cytometry in Oncology and Immunology 麻豆原创 Size (2020-2031)
6.2 North America Flow Cytometry in Oncology and Immunology 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Country (2020-2025)
6.4 North America Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Flow Cytometry in Oncology and Immunology 麻豆原创 Size (2020-2031)
7.2 Europe Flow Cytometry in Oncology and Immunology 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Country (2020-2025)
7.4 Europe Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Flow Cytometry in Oncology and Immunology 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Flow Cytometry in Oncology and Immunology 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Flow Cytometry in Oncology and Immunology 麻豆原创 Size (2020-2031)
9.2 Latin America Flow Cytometry in Oncology and Immunology 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Flow Cytometry in Oncology and Immunology 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Flow Cytometry in Oncology and Immunology 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Flow Cytometry in Oncology and Immunology 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent
11.1.1 Agilent Company Details
11.1.2 Agilent Business Overview
11.1.3 Agilent Flow Cytometry in Oncology and Immunology Introduction
11.1.4 Agilent Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.1.5 Agilent Recent Development
11.2 ABYNTEK BIOPHARMA
11.2.1 ABYNTEK BIOPHARMA Company Details
11.2.2 ABYNTEK BIOPHARMA Business Overview
11.2.3 ABYNTEK BIOPHARMA Flow Cytometry in Oncology and Immunology Introduction
11.2.4 ABYNTEK BIOPHARMA Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.2.5 ABYNTEK BIOPHARMA Recent Development
11.3 Bio-Rad Laboratories
11.3.1 Bio-Rad Laboratories Company Details
11.3.2 Bio-Rad Laboratories Business Overview
11.3.3 Bio-Rad Laboratories Flow Cytometry in Oncology and Immunology Introduction
11.3.4 Bio-Rad Laboratories Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.3.5 Bio-Rad Laboratories Recent Development
11.4 Cell Signaling Technology
11.4.1 Cell Signaling Technology Company Details
11.4.2 Cell Signaling Technology Business Overview
11.4.3 Cell Signaling Technology Flow Cytometry in Oncology and Immunology Introduction
11.4.4 Cell Signaling Technology Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.4.5 Cell Signaling Technology Recent Development
11.5 Cytek Biosciences
11.5.1 Cytek Biosciences Company Details
11.5.2 Cytek Biosciences Business Overview
11.5.3 Cytek Biosciences Flow Cytometry in Oncology and Immunology Introduction
11.5.4 Cytek Biosciences Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.5.5 Cytek Biosciences Recent Development
11.6 Danaher Corporation,
11.6.1 Danaher Corporation, Company Details
11.6.2 Danaher Corporation, Business Overview
11.6.3 Danaher Corporation, Flow Cytometry in Oncology and Immunology Introduction
11.6.4 Danaher Corporation, Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.6.5 Danaher Corporation, Recent Development
11.7 DiaSorin S.p.A (Luminex Corporation),
11.7.1 DiaSorin S.p.A (Luminex Corporation), Company Details
11.7.2 DiaSorin S.p.A (Luminex Corporation), Business Overview
11.7.3 DiaSorin S.p.A (Luminex Corporation), Flow Cytometry in Oncology and Immunology Introduction
11.7.4 DiaSorin S.p.A (Luminex Corporation), Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.7.5 DiaSorin S.p.A (Luminex Corporation), Recent Development
11.8 Enzi Biochem Inc
11.8.1 Enzi Biochem Inc Company Details
11.8.2 Enzi Biochem Inc Business Overview
11.8.3 Enzi Biochem Inc Flow Cytometry in Oncology and Immunology Introduction
11.8.4 Enzi Biochem Inc Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.8.5 Enzi Biochem Inc Recent Development
11.9 Laboratory Corporation of America Holdings,
11.9.1 Laboratory Corporation of America Holdings, Company Details
11.9.2 Laboratory Corporation of America Holdings, Business Overview
11.9.3 Laboratory Corporation of America Holdings, Flow Cytometry in Oncology and Immunology Introduction
11.9.4 Laboratory Corporation of America Holdings, Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.9.5 Laboratory Corporation of America Holdings, Recent Development
11.10 Merck KGaA
11.10.1 Merck KGaA Company Details
11.10.2 Merck KGaA Business Overview
11.10.3 Merck KGaA Flow Cytometry in Oncology and Immunology Introduction
11.10.4 Merck KGaA Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.10.5 Merck KGaA Recent Development
11.11 Miltenyi Biotec
11.11.1 Miltenyi Biotec Company Details
11.11.2 Miltenyi Biotec Business Overview
11.11.3 Miltenyi Biotec Flow Cytometry in Oncology and Immunology Introduction
11.11.4 Miltenyi Biotec Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.11.5 Miltenyi Biotec Recent Development
11.12 NeoGenomics Laboratories
11.12.1 NeoGenomics Laboratories Company Details
11.12.2 NeoGenomics Laboratories Business Overview
11.12.3 NeoGenomics Laboratories Flow Cytometry in Oncology and Immunology Introduction
11.12.4 NeoGenomics Laboratories Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.12.5 NeoGenomics Laboratories Recent Development
11.13 OPKO Health
11.13.1 OPKO Health Company Details
11.13.2 OPKO Health Business Overview
11.13.3 OPKO Health Flow Cytometry in Oncology and Immunology Introduction
11.13.4 OPKO Health Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.13.5 OPKO Health Recent Development
11.14 Sony Group Corporation
11.14.1 Sony Group Corporation Company Details
11.14.2 Sony Group Corporation Business Overview
11.14.3 Sony Group Corporation Flow Cytometry in Oncology and Immunology Introduction
11.14.4 Sony Group Corporation Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.14.5 Sony Group Corporation Recent Development
11.15 Thermo Fisher Scientific Inc.
11.15.1 Thermo Fisher Scientific Inc. Company Details
11.15.2 Thermo Fisher Scientific Inc. Business Overview
11.15.3 Thermo Fisher Scientific Inc. Flow Cytometry in Oncology and Immunology Introduction
11.15.4 Thermo Fisher Scientific Inc. Revenue in Flow Cytometry in Oncology and Immunology Business (2020-2025)
11.15.5 Thermo Fisher Scientific Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
Agilent
ABYNTEK BIOPHARMA
Bio-Rad Laboratories
Cell Signaling Technology
Cytek Biosciences
Danaher Corporation,
DiaSorin S.p.A (Luminex Corporation),
Enzi Biochem Inc
Laboratory Corporation of America Holdings,
Merck KGaA
Miltenyi Biotec
NeoGenomics Laboratories
OPKO Health
Sony Group Corporation
Thermo Fisher Scientific Inc.
听
听
*If Applicable.
